Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Chemoradiation for Glioblastoma
NCT02092038Phase 1Completed
- Sponsor
- Tampa General Hospital
- Start
- Nov 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Tampa General Hospital. Primary endpoint: toxicity of treatment per Common Toxicity Criteria for Adverse Effects V3.0 at 16 weeks. Started Nov 2014; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02092038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092038.